Tagworks announces the completion of an investment round led by Meneldor (The Netherlands), Oost NL (The Netherlands), and a syndicate of high net-worth private investors. The proceeds of the financing will be used for the clinical development of Tagworks’ lead program.
A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio.
The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a broad scope of TCO linkers and tetrazine activators and their application in selective on-target release and activation of a wide range of constructs, including small molecule prodrugs, antibody-drug conjugates, and caged proteins.
Tagworks reports the development of a new and highly reactive Click-to-Release reaction in the Journal of the American Chemical Society. Great collaboration between Tagworks and SyMO-Chem, Syncom, TU/e , Avipep and Levena. https://pubs.acs.org/doi/abs/10.1021/jacs.0c00531
Tagworks is pleased to announce that on the 10th of October, it won the World ADC Award for Best Publication during the 10th World ADC Summit 2019 in San Diego. The World ADC Awards exist to commend excellence across nine categories within antibody-drug conjugate research and development.
Tagworks applies its Click-to-Release platform for the selective release of anticancer drugs in the tumor microenvironment. The publication Rossin et al. Nature Comm. 2018, 9, 1, 1484, is the result of a collaboration between 5 companies (Tagworks, Avipep, SyMO-Chem, Syncom, Levena) and the Radboud University & Medical Center. It demonstrates strong therapeutic proof of concept of a first in class click-cleavable ADC, expanding the scope of ADC therapy to non-internalizing cancer receptors. Tagworks and partners are pleased that the jury recognised the impact of this novel approach.
World ADC – 9-11 October 2019
“Click chemistry targets antibody-drug conjugates for the clinic”. Nature Biotechnology news reports on the current scope and status of the use of click chemistry in vivo, including Tagworks programs, and concludes that bioorthogonal chemistry, already a workhorse of drug discovery research, is ready for the leap into human testing.https://www.nature.com/articles/d41587-019-00017-4
Tagworks will present the latest developments of their click-cleavable ADC technology at the ACS National Meeting in San Diego, taking place on the 25th-29th August. www.acs.org/content/acs/en/meetings/national-meeting
Tagworks will present the latest developments of their click-to-release technology at the 55th International Conference on Medicinal Chemistry – Interfacing Chemical Biology and Drug Discovery – in Nantes, France, taking place on the 3rd-5th July. www.rict2019.org
Tagworks will present the click-cleavable ADC technology at the CHAINS meeting in Veldhoven, taking place on the 3rd-5th December. www.nwochains.nl
Tagworks will present the click-cleavable ADC technology at the Word ADC meeting in San Diego, taking place on the 12th-15st November.http://worldadc-usa.com